a rapid-acting insulin analog, at its manufacturing facility in Petersburg, Va. Civica will commercialize the medicine for patients in the United States, after completion of development work and ...

studies conducted with non-commercially available analog formulations, or trials conducted with insulin preparations that are no longer commercially available.

A new study in the journal Diabetes Technology & Therapeutics evaluated the effects of a regimen of inhaled technosphere ...

TI has a more rapid onset of action than rapid-acting insulin analogs. In this study, adults with type 1 diabetes initiated a regimen of TI plus insulin degludec after completing the usual-care ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

A Sanofi subsidiary has claimed FDA approval for the first biosimilar of Novo Nordisk's Novolog, an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart.

The global disposable insulin-delivery device market is projected to experience robust growth over the next decade, according to recent industry insights. Valued at USD 14,585.6 million in 2022, the ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...

The 26-week, open-label clinical trial randomized 230 pediatric subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA) in combination with ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...